Oncology

Back to articles

Lapatinib provides new hope for patients with advanced breast cancer

KEY POINT

Lapatinib (Tykerb—GlaxoSmithKline), recently approved by FDA, directly targets specific tumor receptors, making it safer and better tolerated than traditional nonspecific chemotherapy. This new oral drug is indicated in combination with capecitabine (Xeloda—Roche) for advanced or metastatic breast cancer in patients whose tumors overexpress Human Epidermal Receptor Type 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab (Herceptin—Genentech).

SOURCES

Tykerb product information. GlaxoSmithKline; 2007.

Nelson MH et al. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors. Ann Pharmacother 2006;40:261–9.

Geyer CE et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–43.

Muss HB. Targeted therapy for metastatic breast cancer [editorial]. N Engl J Med. 2006;355:2783–5.